178872-69-0

Basic information

• Product Name: 2-(3-Benzyloxypropoxy)ethanol
• Synonyms: 2-(3-Benzyloxypropoxy)ethanol
• CAS NO: 178872-69-0
• Molecular Weight: 210.273
• Mol File: 178872-69-0.mol

Chemical Properties

• CAS DataBase Reference: 2-(3-Benzyloxypropoxy)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Benzyloxypropoxy)ethanol(178872-69-0)
• EPA Substance Registry System: 2-(3-Benzyloxypropoxy)ethanol(178872-69-0)

Safety Data

• Hazardous Substances Data: 178872-69-0(Hazardous Substances Data)

Upstream product

• 4799-68-2 3-benzyloxypropan-1-ol 

Downstream Products

• 188176-85-4 2-(3-benzyloxypropoxy)ethyl 2,3,4-tri-O-acetyl-β-L-fucopyranoside 

Relevant articles and documents

Synthesis of sialyl Lewis X analogues

Sialyl Lewis X (SLex) analogs 2a and 2b were synthesised, where the N-acetyl-D-glucose and the D-galactose units of SLex 1 were replaced with an alkyl and a heteroalkyl spacer. Sulphate ester 6i was also synthesised from alcohol 6b and chlorosulphonic acid. A novel promoter, silver mercaptoethanesulphonate, was used to synthesise α-sialosides 2c, 7b and 7c.

TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.